Gout

Study of 16,598 CAD pts showed in pts w/ normal hsCRP<2mg/L, increasing SUA didnt predict CV/MACE events. But if the hsCRP≥2 mg/L, increasing urate(SUA)was signif. assoc w/ increased MACE. Each 1mg incr in SUA yielded an 11% increase in MACE (adj p < 0.001)… https://t.co/9ehtOcoeBK https://t.co/t9IWQ8WUvY
Dr. John Cush @RheumNow( View Tweet )
Mitochondria: the powerhouse of the cell—but the fuel behind gout flares? #ACR24 @RheumNow https://t.co/lV4dovLV18

Links:

Akhil Sood MD @AkhilSoodMD( View Tweet )

Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV

Links:

Richard Conway @RichardPAConway( View Tweet )
#Gout attack is assoc w 1.5 X MI, MACE in next 30 days @ACRheum @RheumNow #ACR24 https://t.co/7IeFbW6xW8

Links:

Janet Pope @Janetbirdope( View Tweet )

This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baseline, which then dramatically increases during flare. Treating gout properly may ameliorate this. #ACR24 @RheumNow https://t.co/VL8fy3ezjx https://t.co/9XdrG1NG9c

Links:

Richard Conway @RichardPAConway( View Tweet )

Meeting audience conference

ACR 2024 - Day 1 Report

Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx

Links:

Richard Conway @RichardPAConway( View Tweet )
📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA 📍 0747 👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further @RheumNow #ACR24 @LemonReneeNi https://t.co/3YMcI9ha3T

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do we care? Well, GLP-1s associated with higher risk gallstones also... @RheumNow #ACR24 Abstr#0133 https://t.co/nf4R0hQe50 https://t.co/wDrEDeNbpT

Links:

Richard Conway @RichardPAConway( View Tweet )

#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

Links:

Adela Castro @AdelaCastro222( View Tweet )
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

Links:

Patricia Harkins @DrTrishHarkins( View Tweet )
CV risk after gout attack 1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance) @RheumNow #ACR24 year in review Pillinger https://t.co/a2zS8mIw3L

Links:

Eric Dein @ericdeinmd( View Tweet )
Year in review: Can #gout flares increase CV risk? Cipoletta et al - pts with gout may be at inc risk of CV events for at least 30-120 days after flares. Emphasize CV risk mgt in all patients w/ gout. @RheumNow #ACR24 https://t.co/p1aXVgqkuR

Links:

sheila @RHEUMarampa( View Tweet )
Weight Loss from Anti-Obesity Medications Prevents Gout A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower… https://t.co/P1iRjtHgHV https://t.co/MoohUKGvUn
Dr. John Cush @RheumNow( View Tweet )
obese.waist_.jpg

Weight Loss from Anti-Obesity Medications Prevents Gout

Jack Cush, MD

A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower risks of incident gout and recurrent gout flares among overweight or obese

Read Article
An Artificial Intelligence-Based Gout Management System Reduced Chronic Kidney Disease Incident and Improves achieving Target Serum Urate levels. AI lowered incid. of CKD stage≥ 3 by 47%, & incr # achieving target SUA <6mg/dl with(59% vs 26%, p<0.001). https://t.co/INULBvaKF9 https://t.co/fkPgbscOXj

Links:

Dr. John Cush @RheumNow( View Tweet )
NHANES study of 11264 adolescents (12–17 yrs) found Hyperuricemia (≥ 5.5 mg/dL) in 33%, (51% males, 13% females) and was more prevalent with obesity and in non-Hispanic Asians https://t.co/rwUt1Cgg9b https://t.co/dFr1LeX0nC

Links:

Dr. John Cush @RheumNow( View Tweet )
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Dr. Quotes (11.8.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx

Links:

Dr. John Cush @RheumNow( View Tweet )
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush @RheumNow( View Tweet )
switch.jpg

Swapping is Better than Cycling in Psoriatic Arthritis

Jack Cush, MD

A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.

Read Article
Calcium pyrophosphate deposition disease -- a full access, full read review in Lancet Rheumatology. Just published ahttps://buff.ly/3C319CH https://t.co/PxywxvzVCh
Dr. John Cush @RheumNow( View Tweet )
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today! https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw

Links:

Dr. John Cush @RheumNow( View Tweet )
GWAS study of 2.6 million people (120,295 w/ prevalent gout) detected 377 loci & 410 independent genes (149 prev unreported), includes genes of inflammation, epigenetic remodeling, cell osmolarity, NLRP3 activity, & clonal hematopoiesis (CHIP) https://t.co/GmXWtTlJkO https://t.co/xPK2Iy3NRj

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics. Read Post

From the Archives: Rheumatology Dead Word Cemetery

Jack Cush, MD
CTD.jpg
I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say? Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×